A New Era for DNA-Based Medicine

Opening Words (Change the yellow part every week)

Good morning, ! This week we’re diving into the $55B Ambulatory Surgery Center market and its consolidation potential, INOVIO’s breakthrough in DNA-based immunotherapy, and what a landmark FDA approval means for the future of healthcare innovation.

Want to advertise in Healthcare 150? Check out our ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

DATA DIVE

Headline ASCS: A $55B Market Built for Consolidation

Ambulatory Surgery Centers (ASCs) are becoming a more important part of U.S. healthcare delivery, with the market projected to expand from $45.6B in 2024 to $55.3B by 2029, a 3.94% CAGR. The growth story is less about explosive demand and more about the continued migration of surgical procedures from hospitals to lower-cost outpatient settings.

The operating model remains highly fragmented. 55% of ASCs operate with just 1 to 2 operating rooms, while another 31% have 3 to 4, creating a broad acquisition universe for private equity and health systems. Orthopedics (844 centers), pain management (793), and ophthalmology (722) represent established specialty segments where scale and operational standardization could create value.

The economic case is equally compelling. ASCs generated an estimated $1.48B in Medicare savings across California, Florida, and Texas alone, reinforcing their relevance as payers seek to reduce procedural costs.

Bottom line: ASC growth may be modest, but the investment opportunity lies in consolidation, improved facility utilization, and specialty expansion. For acquirers, disciplined execution and payer contracting will matter more than market growth alone.

Read Full Report HERE

COMPANY OF THE WEEK

INOVIO PHARMACEUTICALS

A DNA-based approach to reducing repeat airway surgeries

INOVIO Pharmaceuticals earned a landmark regulatory win on October 30, when the FDA granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis (RRP). The rare, HPV-driven disease causes recurring growths in the airways, often requiring patients to undergo repeated surgeries.

Voceryq is the first FDA-approved plasmid DNA-based immunotherapy in the United States. Rather than removing growths surgically, it is designed to train the immune system to attack cells infected with HPV types 6 and 11, which cause RRP. Treatment combines an intramuscular injection with a device that uses brief electrical pulses to help deliver the DNA into cells.

The clinical signal: in an open-label study of 32 adults, seven of the 26 patients included in the efficacy analysis needed no surgery during the first year after treatment. Those 26 patients had undergone at least three surgeries in the preceding year.

For healthcare business leaders, the significance extends beyond a rare-disease treatment. The approval establishes a U.S. regulatory precedent for plasmid DNA-based immunotherapy, while making specialist adoption and treatment delivery important commercial milestones to watch. It does not establish that INOVIO’s other pipeline candidates will succeed.

The key caveat: this is accelerated approval, supported by a small, open-label study. Post-approval trials must verify clinical benefit. Common adverse reactions included injection-site reactions, headache and fatigue (More)

In partnership with

The ice cream shop that makes money when it's cold

28 Wishes sells ice cream in Los Angeles. Below 70°F, sales fall about 20%. The weather is out of their hands. Rent isn't.

So the owners started putting about $20 a day into Kalshi weather markets, taking the cold side. The days that keep customers away now pay something back.

This is hedging. Big companies have done it for decades, buying protection against bad weather, fuel spikes and rising rates. It used to take a broker, a trading desk, and an order size no corner shop could meet.

Kalshi opens it up. Contracts on weather, fuel prices, inflation, tariffs and regulation, starting at a few dollars. Take a position on the outcome that would hurt you. If it hits, the payout softens it. If it doesn't, the contract expires and the good month was the point.

See how other owners are doing it at Kalshi.com/hedging

COMPETITIVE LANDSCAPE SNAPSHOT

INTERESTING ARTICLES